- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04999592
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT) (PROTECT)
October 2, 2023 updated by: David J. Gagnon
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT): a Randomized-controlled Trial and Microbiome Assessment
Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Pneumonia is an infection of the lungs resulting in alveolar inflammation and fluid or purulent material accumulation.
It is the most common infection after cardiac arrest occurring in up to 65% of patients treated with targeted temperature management.
Pneumonia may result from aspiration during cardiopulmonary resuscitation (CPR), or by introduction of oropharyngeal flora into the lungs during airway management.
Preventing infection after OHCA may: 1) reduce exposure to broad-spectrum antibiotics and subsequent collateral damage, 2) prevent hemodynamic derangements due to local and systemic inflammation, and 3) prevent an association between infection and morbidity and mortality.
These benefits must be balanced with the risk for altering bacterial resistomes in the absence clinical infection.
Accordingly, further study is warranted to understand the risk-to-benefit ratio of prophylactic antibiotics.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David Gagnon, PharmD
- Phone Number: 207-662-1338
- Email: Dgagnon@mmc.org
Study Contact Backup
- Name: Christine Lord, BSN, RN
- Phone Number: 207-662-5432
Study Locations
-
-
Maine
-
Portland, Maine, United States, 04102
- Recruiting
- Maine Medical Center
-
Contact:
- David Gagnon, PharmD
- Phone Number: 207-662-1338
- Email: Dgagnon@mmc.org
-
Contact:
- Christine Lord, BSN, RN
- Phone Number: 207-662-5432
- Email: LordC@mmc.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥18 years of age
- Comatose (do not follow simple verbal commands)
- Have any initial heart rhythm (shockable or non-shockable)
- OHCA including the emergency department
Exclusion Criteria:
- Name on opt-out list
- In-hospital cardiac arrest
- Interval >6 hours from ICU admission to study drug receipt
- Preexisting terminal disease making 180-day survival unlikely
- Refused informed consent
- Emergent coronary artery bypass grafting
- Anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or penicillins)
- Under legal guardianship or prisoner
- Known colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococcus (VRE)
Clinical bacterial infection prior to hospital admission defined as any one of the following:
- Infectious prodrome preceding OHCA
- Active course of antibiotics for infection prior to admission
- Active infection documented in the electronic medical record
- Family or surrogate endorsement of an active infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: No prophylaxis (placebo)
Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted. Administer antibiotics in response to infection. |
Administer antibiotics in response to infection
|
Experimental: Prophylaxis
Antibiotic prophylaxis for 3 days.
Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
|
Ceftriaxone 2 gm IV q12h for 3 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Clinically-diagnosed Early-onset Pneumonia
Time Frame: 4 days
|
Percentage of Participants with Clinically-diagnosed Early-onset Pneumonia occurring <4 days after initiation of mechanical ventilation
|
4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with Microbiologically-confirmed Early-onset Pneumonia
Time Frame: 4 days
|
Percentage of Participants with Microbiologically-confirmed Early-onset Pneumonia occurring <4 days after initiation of mechanical ventilation
|
4 days
|
Percentage of Participants with Microbiologically-confirmed late-onset pneumonia
Time Frame: ≥ 4 days
|
Percentage of Participants with Microbiologically-confirmed late-onset pneumonia occurring ≥4 days after initiation of mechanical ventilation
|
≥ 4 days
|
Percentage of Participants with Clinically-diagnosed late-onset pneumonia
Time Frame: ≥ 4 days
|
Percentage of Participants with Clinically-diagnosed late-onset pneumonia occurring ≥4 days after initiation of mechanical ventilation
|
≥ 4 days
|
Percentage of Participants with non-pulmonary infections
Time Frame: During the intervention and immediately after the intervention until hospital discharge, up to 6 months
|
Percentage of Participants with non-pulmonary infections
|
During the intervention and immediately after the intervention until hospital discharge, up to 6 months
|
ICU-free days during admission
Time Frame: 28 days
|
ICU-free days in the first 28 days of admission
|
28 days
|
Mechanical ventilator-free days during admission
Time Frame: 28 days
|
Mechanical ventilator-free days in the first 28 days of admission
|
28 days
|
ICU Length of Stay
Time Frame: During the intervention and immediately after the intervention until death or ICU discharge measured in days, up to 6 months
|
Intensive care unit length of stay
|
During the intervention and immediately after the intervention until death or ICU discharge measured in days, up to 6 months
|
Hospital Length of Stay
Time Frame: During the intervention and immediately after the intervention until death or hospital discharge measured in days, up to 6 months
|
hospital length of stay
|
During the intervention and immediately after the intervention until death or hospital discharge measured in days, up to 6 months
|
Percentage of Participants who die in the intensive care unit
Time Frame: During the intervention and immediately after the intervention until death or ICU discharge
|
Percentage of Participants who die in the intensive care unit
|
During the intervention and immediately after the intervention until death or ICU discharge
|
Percentage of Participants who Die in the Hospital
Time Frame: During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants who Die in the Hospital during admission
|
During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants Discharged Home or to Rehabilitation
Time Frame: During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants Discharged Home or to Rehabilitation
|
During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants Transferred to Another Hospital
Time Frame: During the intervention and immediately after the intervention until death or hospital transfer
|
Percentage of Participants Transferred to Another Hospital
|
During the intervention and immediately after the intervention until death or hospital transfer
|
Percentage of Participants with a Good Functional Outcome at Hospital Discharge
Time Frame: After the intervention at the time the participant is discharged from the hospital
|
Percentage of Participants with a Good Functional Outcome at Hospital Discharge Good functional outcome will be mRS ≤0-3 of or a CPC 1-2
|
After the intervention at the time the participant is discharged from the hospital
|
13. Percentage of Participants with a Good Functional Outcome at 6 Months Post-hospital Discharge
Time Frame: 6 months post-hospital discharge
|
13. Percentage of Participants with a Good Functional Outcome at 6 Months Post-hospital Discharge.
Good functional outcome will be mRS ≤0-3 of or a CPC 1-2
|
6 months post-hospital discharge
|
Percentage of Participants with Clostridioides difficile-associated Diarrhea
Time Frame: During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants with Clostridioides difficile-associated Diarrhea
|
During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants with Type One Hypersensitivity Reactions
Time Frame: Three days
|
Percentage of Participants with Type One (immediate-type) hypersensitivity reactions
|
Three days
|
Percentage of Participants with Gallbladder disease
Time Frame: During the intervention and immediately after the intervention until death or hospital discharge
|
Percentage of Participants with Gallbladder disease
|
During the intervention and immediately after the intervention until death or hospital discharge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 20, 2021
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
June 30, 2024
Study Registration Dates
First Submitted
July 8, 2021
First Submitted That Met QC Criteria
August 2, 2021
First Posted (Actual)
August 11, 2021
Study Record Updates
Last Update Posted (Actual)
October 3, 2023
Last Update Submitted That Met QC Criteria
October 2, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1P20GM139745-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Standard of care without prophylaxis
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado...CompletedDisproportionate Shape | Expanded Fat PadsUnited States
-
Läkarexpressen ABLund University; Region Skane; Region Halland; Västra GötalandsregionenCompleted
-
University of PennsylvaniaMedical University of South Carolina; NYU Langone Health; National Institute... and other collaboratorsTerminatedHead and Neck Cancer | Oral MucositisUnited States
-
NRG OncologyNational Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern... and other collaboratorsRecruitingHER2-positive Breast CancerUnited States, Puerto Rico
-
Walter Reed National Military Medical CenterCompletedFunctional ConstipationUnited States
-
Germans Trias i Pujol HospitalUnknownEmergence Delirium | Preoperative Anxiety | Maladaptive Postoperative BehaviorSpain
-
Min SuNot yet recruitingPostoperative Pulmonary ComplicationsChina
-
University Hospital, LilleCompletedVentral HerniaFrance
-
Sharp HealthCareGE Healthcare; Sharp Mary Birch Hospital for Women & NewbornsCompletedPremature Infant | Extreme Prematurity | Extremely Low Birth WeightUnited States
-
Legacy Health SystemCompletedBreast CancerUnited States